| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Department of Microbiology and Immunology, New York Medical College, Valhalla, New York
Requests for reprints: Raj K. Tiwari, Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595. Phone: 914-594-4870; E-mail: raj_tiwari{at}nymc.edu. Asesh Banerjee, Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595. Phone: 914-594-4814; E-mail: asesh_banerjee{at}nymc.edu.
Heat shock protein gp96 induces a tumor-specific protective immunity in a variety of experimental tumor models. Because the primary sequences of the glycoprotein, gp96 are identical between tumor and normal tissues, the peptides associated with gp96 and/or the posttranslational modifications of gp96, determine its immunogenicity. Gp96-associated peptides constitute the antigenic repertoire of the source tissue; thus, purified gp96-peptide complexes have clinical significance as autologous cancer vaccines. However, the role of altered glycosylation and its contribution in the biological as well as immunologic activity of gp96 still remains uncharacterized. We examined the cancer-specific glycosylation patterns of gp96. To this end, monosaccharide compositions of gp96 were compared between normal rat prostate and two cancerous rat prostate tissues, nonmetastatic/androgen-dependent Dunning G and metastatic/androgen-independent MAT-LyLu, as well as two human nonmetastatic prostate cancer cell lines, androgen-dependent LnCaP and androgen-independent DU145. Marked differences were observed between the gp96 monosaccharide compositions of the normal and cancerous tissues. Furthermore, gp96 molecules from more aggressive cellular transformations were found to carry decreasing quantities of several monosaccharides as well as sum total content of neutral and amino sugars. We believe that the unique glycosylation patterns contribute to cellular phenotype and that the posttranslational modifications of gp96 may affect its functional attributes.
This article has been cited by other articles:
![]() |
R. Suriano, S. K Ghosh, D. Chaudhuri, A. Mittelman, A. Banerjee, and R. K Tiwari Sialic acid content of tissue-specific gp96 and its potential role in modulating gp96-macrophage interactions Glycobiology, December 1, 2009; 19(12): 1427 - 1435. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Na, H. Kim, M. P. Moyer, C. Pothoulakis, and J. T. LaMont gp96 Is a Human Colonocyte Plasma Membrane Binding Protein for Clostridium difficile Toxin A Infect. Immun., July 1, 2008; 76(7): 2862 - 2871. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F. Valenzuela, K. E. Pace, P. V. Cabrera, R. White, K. Porvari, H. Kaija, P. Vihko, and L. G. Baum O-Glycosylation Regulates LNCaP Prostate Cancer Cell Susceptibility to Apoptosis Induced by Galectin-1 Cancer Res., July 1, 2007; 67(13): 6155 - 6162. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |